AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention

• Phase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more migraine days per month.
• Atogepant (QULIPTA®) demonstrated superior efficacy across key clinical and functional outcomes, including reductions in monthly migraine days and improvements in headache-related disability, daily functioning and cognitive function.
• 25% of Canadian households are impacted by migraine.

MONTREAL, Oct. 29, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology. The randomized, double-blind, head-to-head study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) 60 mg, once daily, compared with the highest tolerated dose of topiramate (50 mg, 75 mg or 100 mg per day) for the preventive treatment of migraine in adults.

The results of the TEMPLE study demonstrated that atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, achieved superior tolerability and efficacy compared with topiramate, a medication also approved for migraine prevention.